Caribou Biosciences (CRBU) Stock News

Caribou Biosciences (Nasdaq: CRBU) announced late-breaking presentations at the 2026 Tandem Meetings (Feb 4-7, Salt Lake City) featuring updated clinical and new translational data for two allogeneic CAR-T programs.

Vispa-cel (CB-010) ANTLER poster (Feb 5) reports efficacy and durability reportedly on par with autologous CAR-T in second-line large B cell lymphoma. CB-011 CaMMouflage oral (Feb 7) shows CAR-T expansion correlating with deep, durable responses and supports the selected regimen for dose expansion. Abstracts are available at tandemmeetings.com and presentations will be posted on Caribou’s Scientific Publications page after the event.

Caribou Biosciences (Nasdaq: CRBU) will host an in-person and virtual KOL panel at the 67th ASH Annual Meeting on Dec 6, 2025 at 7:30 AM ET to discuss vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy. The session will examine how vispa-cel may broaden access to second-line large B cell lymphoma care by enabling CAR-T delivery in community hospitals and academic centers.

The event is moderated by Tina Albertson, MD, PhD, and features clinicians from Utah Cancer Specialists, Bozeman Health, Medical College of Wisconsin, and University of Kansas Cancer Center. In-person attendance is invite-only; a webcast and replay will be available and registration is on the company Events page.

Caribou Biosciences (Nasdaq: CRBU) reported Q3 2025 results and clinical updates on Nov 12, 2025. Key clinical data show vispa-cel (CB-010) ANTLER phase 1 confirmatory cohort (N=22) achieved 82% ORR, 64% CR, and 51% 12‑month PFS (data cutoff Sep 29, 2025). An optimized vispa-cel profile (N=35) showed 86% ORR, 63% CR, and 53% 12‑month PFS (median follow‑up 11.8 months).

CB-011 (CaMMouflage phase 1) dose‑escalation RDE 450M cells; BCMA‑naïve RDE cohort (12 pts, cutoff Sep 24, 2025) showed 92% ORR, 75% ≥CR, and 91% MRD‑negativity (10/11 evaluable). Company had $159.2M cash and expects funding into 2H 2027 while exploring options to fully fund pivotal vispa-cel trial.

Caribou Biosciences (Nasdaq: CRBU) said company management will participate in investor conferences in November and December 2025.

Scheduled appearances: 2025 Truist Securities BioPharma Symposium, New York — November 6, 2025, and 8th Annual Evercore Healthcare Conference, Coral Gables, FL — December 2, 2025 with a fireside chat at 8:45–9:05 AM ET. Webcasts and event links will be posted on the company Events page and will be available for at least 30 days after each event.

Caribou Biosciences (Nasdaq: CRBU) reported positive ANTLER Phase 1 data for allogeneic CAR-T therapy vispa-cel (CB-010) with confirmatory cohort (N=22) showing 82% ORR, 64% CR and 51% 12‑month PFS (efficacy cutoff Sep 29, 2025). An optimized-profile cohort (N=35) showed 86% ORR, 63% CR and 53% 12‑month PFS with median follow-up 11.8 months. Safety (safety cutoff Sep 2, 2025) across N=84 shows manageable events: thrombocytopenia 62%, CRS 55% (grade ≥3 5%), no GvHD and no ≥grade 3 ICANS in key cohorts. Company plans a randomized pivotal Phase 3 (~250 patients) in 2L LBCL per FDA recommendation and held a webcast on Nov 3, 2025.

Caribou Biosciences (Nasdaq: CRBU) reported first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The 450x10^6 CAR-T cell dose is the recommended dose for expansion (RDE); dose expansion is planned to start by year-end with data expected in 2026. In 12 BCMA-naïve patients at the RDE (median follow-up 8.3 months) the trial showed 92% ORR, 75% ≥CR, and 91% MRD negativity (≤10^-5). Safety was described as manageable but included cytopenias, infections and isolated serious adverse events.

Caribou Biosciences (Nasdaq: CRBU) will host a live webcast at 8:00 am ET on Monday, November 3, 2025 to report new clinical data.

The presentation will cover updated results from the ANTLER Phase 1 trial of vispacabtagene regedleucel (vispa-cel; formerly CB-010) in relapsed or refractory B cell non-Hodgkin lymphoma and the first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The company will also outline its anticipated pivotal Phase 3 trial design for vispa-cel and next steps for CB-011 development.

A live webcast is available on Caribou’s Events page and the archived webcast will be accessible for 30 days after the event.

Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced its participation in the upcoming Citi 2025 Biopharma Back to School Conference. Rachel Haurwitz, PhD, the company's president and CEO, will engage in a fireside chat on September 3, 2025 at 2:30 PM EDT.

The presentation will be accessible through a webcast on Caribou's website's Events page and will remain available for at least 30 days following the event.

Caribou Biosciences (Nasdaq: CRBU) reported Q2 2025 financial results and provided updates on its clinical programs. The company ended Q2 with $183.9 million in cash, expected to fund operations into H2 2027. Key financial metrics include $2.7 million in licensing revenue and a GAAP net loss of $54.1 million ($0.58 per share).

Clinical highlights include completion of enrollment for both the CB-010 ANTLER Phase 1 trial in large B cell lymphoma and the dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in multiple myeloma. The company plans to present robust datasets from both programs in H2 2025, with CB-010 showing potential outcomes comparable to approved autologous CAR-T cell therapies.